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Abstract
Introduction: The estrogen receptor (ER) co-regulator proline glutamic acid and leucine-rich protein 1 (PELP1) is a
proto-oncogene that modulates epigenetic changes on ER target gene promoters via interactions with lysine-specific
histone demethylase 1 (KDM1). In this study, we assessed the therapeutic potential of targeting the PELP1-KDM1 axis in
vivo using liposomal (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; DOPC) siRNA to downregulate PELP1 expression
and KDM1 inhibitors, pargyline and N-((1S)-3-(3-(trans-2-aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)propyl)
benzamide using preclinical models.
Methods: Preclinical xenograft models were used to test the efficacy of drugs in vivo. Ki-67 and terminal
deoxynucleotidyl transferase dUTP nick end-labeling immunohistochemical analysis of epigenetic markers was
performed on tumor tissues. The in vitro effect of PELP1-KDM axis blockers was tested using proliferation, reporter
gene, chromatin immunoprecipitation and real-time RT-PCR assays. The efficacy of the KDM1 targeting drugs alone
or in combination with letrozole and tamoxifen was tested using therapy-resistant model cells.
Results: Treatment of ER-positive xenograft-based breast tumors with PELP1-siRNA-DOPC or pargyline reduced
tumor volume by 58.6% and 62%, respectively. In a postmenopausal model, in which tumor growth is stimulated
solely by local estrogen synthesis, daily pargyline treatment reduced tumor volume by 78%. Immunohistochemical
analysis of excised tumors revealed a combined decrease in cellular proliferation, induction of apoptosis and
upregulation of inhibitory epigenetic modifications. Pharmacological inhibition of KDM1 in vitro increased inhibitory
histone mark dimethylation of histone H3 at lysine 9 (H3K9me2) and decreased histone activation mark acetylation
of H3K9 (H3K9Ac) on ER target gene promoters. Combining KDM1 targeting drugs with current endocrine
therapies substantially impeded growth and restored sensitivity of therapy-resistant breast cancer cells to
treatment.
Conclusion: Our results suggest inhibition of PELP1-KDM1-mediated histone modifications as a potential
therapeutic strategy for blocking breast cancer progression and therapy resistance.
Introduction
Breast cancer accounts for over one-quarter of all cancer
diagnoses, with an estimated 200,000 new cases annually
[1]. Despite recent advances in diagnosis and treatment
strategies, nearly 40,000 women will die of this disease in
2011 [1]. The hormone-dependent nature of breast cancer
and the important role of estrogen receptor alpha (ERa)
in initiation and progression supported development of
pharmacologic agents to either reduce circulating estrogen
levels or modulate ERa functions [2,3]. Targeted endo-
crine therapies significantly reduce mortality in patients
with hormone-responsive (ERa-positive) tumors. How-
ever, both de novo and acquired therapy resistance limits
treatment efficacy [4].
ERa transcriptional activity is not only regulated by
steroid hormones alone but also requires co-regulatory
proteins [5,6]. Following hormone stimulation, multi-
protein complexes containing ERa co-regulators and
transcriptional regulators assemble to regulate gene
transcription [6]. ERa co-regulatory proteins are tightly
regulated under normal conditions, with misexpression
primarily reported in the literature in association with
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a number of disease states. Over one-third of the
nearly 300 distinct co-regulators identified are overex-
pressed or underexpressed in human cancers; 38% of
co-regulators are overexpressed in breast cancer [7].
These findings suggest that deregulated co-regulator
expression may promote carcinogenesis and/or pro-
gression of endocrine-related cancers. ERa-associated
co-regulator misexpression contributes to ERa activity
and often correlates with poor prognosis [8,9]. Conse-
quently, co-regulator expression represents an indirect
means of targeting ERa activity.
Estrogen-induced breast carcinogenesis is characterized
by aberrant histone modifications [10]. Ligand-bound
ERa promotes various histone modifications on target
gene promoters and such modifications are facilitated by
ERa co-regulatory proteins. Regulatory effects of histone
acetylation and phosphorylation have been extensively
characterized. However, the role of histone methylation
remains understudied. Unlike acetylation, which gener-
ally correlates with gene activation, the consequences of
histone methylation are site dependent. For example, his-
tone H3 lysine 4 dimethylation (H3K4me2) on ERa tar-
get gene promoters correlates with transcriptional
activation, while lysine 9 dimethylation (H3K9me2)
associates with repression [11,12]. Previous studies show
recruitment of lysine-specific histone demethylase 1
(KDM1) to a significant fraction of ERa target genes [13].
Unlike genetic alterations, epigenetic changes are reversi-
ble and therefore represent a promising therapeutic
target.
Emerging evidence implicates a functional role of ERa
co-regulator proline glutamic acid and leucine-rich protein
1 (PELP1) in the oncogenic properties of cancer cells [14].
PELP1 deregulation occurs within several hormone-
responsive malignancies including breast cancer, ovarian
cancer and prostate cancer [15]. In a subset of human
breast tumors, both PELP1 expression and localization are
altered [16]; expression during breast cancer progression
is associated with more invasive disease [16,17]. In a pre-
clinical study of ERa-positive breast cancer patients,
PELP1 expression was identified as an independent prog-
nostic biomarker in assessing clinical outcome; elevated
expression associated positively with poor prognosis [17].
Acting as a scaffolding protein, PELP1 coordinates various
signaling pathways with ERa by modulating interactions
with known oncogenes and cytosolic kinases [15]. PELP1
deregulation correlates with increased aromatase expres-
sion resulting in tumor proliferation via local estrogen
synthesis [14]. Recent studies indicated that PELP1 inter-
action with KDM1 plays a key role in PELP1-mediated
oncogenic functions [18]. Although such findings suggest
a role for the PELP1-KDM1 axis in breast cancer progres-
sion, the therapeutic potential of targeting the PELP1-
KDM1 axis is unknown.
In the present article we target the PELP1-KDM1 axis
using a nanoliposomal formulation of PELP1-siRNA-
1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC)
administered systemically and KDM1 inhibitors in xeno-
graft-based preclinical breast tumor models. Treatment
of ERa-positive tumors with PELP1-siRNA-liposomes
or pargyline significantly reduced tumor volume.
Further, combining KDM1 targeting drugs with current
endocrine therapies substantially impeded growth and
restored sensitivity of therapy-resistant breast cancer
cells. Our data suggest inhibiting PELP1-KDM1-
mediated histone modifications as a potential therapeu-
tic strategy for blocking disease progression and therapy
resistance among breast cancer patients.
Materials and methods
Cell lines and reagents
Human breast cancer MCF-7 cells were obtained from
American Type Culture Collection (Manassas, VA, USA).
All of the proposed cells were passaged in the user’s
laboratory for fewer than 6 months after receipt or resus-
citation. MCF-7-PELP1 cells [19], MCF-7-HER2 [20],
MCF-7-TamR cells [20] and MCF-7-LTLTca cells [21]
have been described earlier. MCF-7 cells transfected with
control vector were used as controls. MCF-7-LTLTca
and MCF-7-TamR cells were cultured in Phenol red-free
RPMI medium containing 5% dextran charcoal-treated
serum supplemented with either 1 μmol/l letrozole or
1 μmol/l tamoxifen, respectively.
Estradiol (catalogue number E2257), tamoxifen (catalo-
gue number H7904), androstenedione (catalogue number
A9630) and pargyline (catalogue number P8013) were pur-
chased from Sigma (St Louis, MO, USA). N-((1S)-3-(3-
(trans-2-aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)
propyl)benzamide (NCL-1) was synthesized as previously
described [22].
The anti-PELP1 (catalogue number 300-180A) and anti-
KDM1 (catalogue number A300-215A) antibodies were
purchased from Bethyl Laboratories (Montgomery, TX,
USA). Anti-GFP antibody (catalogue number 632381) was
purchased from Clontech (Mountain View, CA, USA).
Anti-dimethyl-H3K4 (catalogue number 07-030) and anti-
H3K9 (catalogue number 07-441) antibodies were
purchased from Upstate (Chicago, IL, USA). Anti-acetyl-
histone H3 (lys9; catalogue number 9671) was purchased
from Cell Signaling (Danvers, MA, USA).
The terminal deoxynucleotidyl transferase dUTP
nick end-labeling (TUNEL) kit (catalogue number
11684795910) for apoptosis detection was purchased from
Roche (Mannheim, Germany) and Ki-67 anti human
Clone MiB-1 antibody (catalogue number M7240) was
purchased from Dako (Carpinteria, CA, USA). The PELP1
(catalogue number L004463-00-0050) and KDM1 (catalo-
gue number L-009223-00-0005) nontargeting control
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(catalogue number D-001810-01-05) SMARTpool siRNA
duplexes were purchased from Dharmacon (Lafayette, CO,
USA).
Real-time PCR
Cells were harvested with Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) and total RNA was isolated according
to the manufacturer’s instructions. cDNA synthesis was
performed using the Superscript III RT-PCR kit (Invitro-
gen). Real-time PCR was carried out using a Cepheid
SmartCycler II (Sunnyvale, CA, USA) with gene-specific
real-time PCR primers. Results were normalized to actin
transcript levels and the difference in fold expression was
calculated using the ΔΔCT method. The primers for aro-
matase were 5’-AAATCCAGACTGTTATTGGTGA-
GAG-3’ (sense) and 5’-GTAGCCATCGATTACATCATC
TTCT-3’ (antisense), and the primers for GREB1C were
5’-GGCAGGACCAGCTTCTGA-3’ (sense) and 5’-CTGT
TCCCACCACCTTGG-3’ (antisense).
Cell proliferation assay
The cell proliferation rate was measured using a 96-well
format with Cell Titer-Glo Luminescent Cell Viability
Assay (G7572; Promega). Cells (5×103) were plated in
each well of Corning® 96-well, clear, flat-bottom, opaque
wall microplates and cultured in RPMI media containing
2.5% Dextran Charcoal (DCC) treated serum for 24 hours
and followed by treatment with or without estradiol
(100 nM/well) for an additional 72 hours. Luminescence
was recorded using automatic Fluoroskan Luminometer as
per the manufacturer’s recommendations. All experiments
are carried out using three biological replicates.
Chromatin immunoprecipitation
The chromatin immunoprecipitation analysis was per-
formed as described previously [18]. Briefly, MCF-7,
MCF-7-HER2 and MCF-7-PELP1 cells were cross-linked
using 1% formaldehyde, and the chromatin was subjected
to immunoprecipitation using the indicated antibodies.
Isotype-specific IgG was used as a control. DNA was re-
suspended in 50 µl Tris-EDTA buffer (TE) buffer and
used for real-time PCR amplification using the gene-
specific primers. The primers for aromatase PI.3/11
promoter regions were 5’-CAAGGTCAGAAATGCTG-
CAA-3’ (sense) and 5’-AGCTCCTGTTGCTTCAG-




Preparation of liposomal siRNA
For in vivo delivery, PELP1 siRNA was incorporated into
DOPC nanoliposomes as described previously [23,24].
Briefly, siRNA and DOPC were mixed in excess tertiary
butanol at a ratio of 1:10 (w/w) respectively. Subse-
quently, Tween 20 was added to the mixture at the ratio
of 1:19 (Tween 20:siRNA/DOPC). The mixture was vor-
texed and frozen in an acetone/dry-ice bath and lyophi-
lized. For in vivo administration, the mixture was
hydrated with 0.9% saline to a concentration of 15 μg/
ml, and 200 to 250 μl of the mixture was used for each
injection. siRNA for preparation of liposomes were pur-
chased from Sigma. The targeted sequences used were
5’-CCACAGAGCCUGACUCCUA-3’ for PELP1 and 5’-
UUCUCCGAACGUGUCACGU-3’ for control.
Tumorigenesis assays
All animal experiments were performed after obtaining
University of Texas Health Science Center, San Antonio
Institutional Animal Care and Use Committee approval,
and animals were housed in accordance with the Univer-
sity of Texas Health Science Center, San Antonio institu-
tional protocol for animal experiments.
For tumorigenesis studies, model cells (5×106) were
injected into the mammary fatpad of 6-week-old to 7-
week-old female nude mice (n = 10 per group) as
described elsewhere [16]. Athymic nude mice (nu/nu)
were injected with control MCF-7 cells or with MCF-7
cells that overexpress PELP1 by mixing them with an
equal volume of Matrigel™ Matrix (BD Biosciences San
Jose, CA, USA). In the premenopausal model, mice
received one 60-day release pellet containing 0.72 mg 17b-
estradiol (Innovative Research of America, Sarasota, FL,
USA) 1 week before implantation of cells. For the postme-
nopausal model, mice were subjected to ovariectomy 1
week prior to tumor cell inoculation. Owing to the defi-
ciency of adrenal androgens in this model, athymic mice
were supplemented with subcutaneous injections of the
aromatase substrate androstenedione (100 µg/day) for the
duration of the experiment as described for the postmeno-
pausal model [25].
To examine the effects of PELP1 siRNA therapy on
tumor growth, treatment was initiated 1 week after
intraperitoneal injection of tumor cells. Mice were ran-
domly assigned to two groups (n = 10 mice per group):
control siRNA-DOPC (150 μg/kg intraperitoneally twice
weekly), and PELP1 siRNA-DOPC (150 μg/kg intraperi-
toneally twice weekly). The mice were monitored daily
for adverse toxic effects. Tumor growth was measured
with a caliper at weekly intervals, and the volume was
calculated using a modified ellipsoidal formula:
Tumor volume = 1/2(L×W2)
where L is the longitudinal diameter and W is the trans-
verse diameter. At the end of each experiment, the mice
were euthanized, and the tumors were removed, weighed
and processed for immunohistochemistry (IHC) staining.
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Immunohistochemistry
Immunohistochemical analysis was performed as
described elsewhere [14]. Briefly, tumor sections were
incubated overnight with the primary antibodies PELP1
(1:750), H3K9me2 (1:50), H3K4me2 (1:50), H3K9ac
(1:50) and Ki-67 (1:150) in conjunction with proper con-
trols. The sections were then washed three times with
0.05% Tween, incubated with secondary antibody for
1 hour, washed three times with 0.05% Tween in PBS,
visualized by 3,3’-diaminobenzidine (DAB) substrateand
counterstained with hematoxylin QS (Vector Lab, Bur-
lingame, CA, USA). The proliferative index was calcu-
lated as the percentage of Ki-67-positive cells in 10
randomly selected microscopic fields at 40× per slide.
TUNEL analysis was performed using the in situ Cell
Death Detection Kit (Roche, Indianapolis, IN, USA) as
per the manufacturer’s protocol, and 10 randomly
selected microscopic fields in each group were used to
calculate the relative ratio of TUNEL-positive cells. The
H3K9me2 and H3K4me2 expression of tumors was
quantified as 100× the number of positive cells divided
by the total number of cells counted under 40× magnifi-
cation in 10 randomly selected areas in each tumor
sample.
Statistical analysis
Statistical differences among groups were analyzed with
either the t test or analysis of variance when appropriate
using Prism software (Irvine, CA, USA).
Results
PELP1 knockdown reduces proliferation and enhances
inhibitory epigenetic modifications
We previously demonstrated the feasibility of silencing
PELP1 gene expression in vivo through systemic adminis-
tration of PELP1 siRNA [26]. To determine the in vivo sig-
nificance of PELP1 in breast cancer progression, siRNA in
a nanoliposomal formulation (PELP1-siRNA-DOPC) was
used to silence PELP1 gene expression. Several published
studies have validated the delivery and therapeutic efficacy
of DOPC-based siRNA nanoliposomes to knock down
expression of specific genes in vivo [23,27,28]. Adult
female athymic nu/nu mice received a 17b-estradiol pellet
(0.72 mg/pellet, 60-day release) 1 week prior to subcuta-
neous injection of MCF-7 breast cancer model cells
(5×106 cells) into both flanks. Based on previous dose-
response experiments, 150 μg/kg liposomal siRNA every
72 hours effectively downregulates gene expression in
vivo. Mice bearing xenografts were randomly assigned to
receive either control nontargeting siRNA-DOPC or
PELP1-siRNA-DOPC via an intraperitoneal route. Follow-
ing 6 weeks of treatment, mice were euthanized, and
tumors were harvested and evaluated for PELP1 expres-
sion by IHC.
Excised tumors from mice treated with PELP1-siRNA-
DOPC had markedly low expression of PELP1 (Figure 1A).
Compared with controls, mice treated with PELP1-siRNA-
DOPC had a significant reduction in tumor volume by
58.6% (P < 0.001) (Figure 1B) without causing any observa-
ble signs of distress or changes in behavior, mobility or
weight loss (data not shown), indicating low treatment
toxicity. Tumor growth is regulated by both tumor cell
proliferation and apoptosis. We therefore performed
immunohistochemical analysis of Ki-67 as a marker of
cellular proliferation and TUNEL assay to measure apopto-
sis. PELP1-siRNA-DOPC treatment significantly decreased
tumor cell proliferation and induced apoptosis (Figure
S1A,B in Additional file 1) compared with control siRNA-
DOPC treatment. Additionally, PELP1-siRNA-DOPC-trea-
ted tumors exhibited decreased staining of the activation
histone marks H3K4me2 and H3K9ac while increasing the
inhibitory epigenetic mark H3K9me2 compared with con-
trols (Figure 1C). Our results indicate that functional
PELP1 axis is necessary for optimal proliferation of breast
cancer cells and plays a critical role in modulating epige-
netic marks on histone tails needed for proliferation
in vivo.
Pargyline reduces estrogen-driven proliferation of breast
cancer cells
PELP1 is an ERa co-regulator [15] that functions as a
proto-oncogene to promote breast tumor cell proliferation
[16]. PELP1 deregulation contributes to local estrogen
synthesis [14] and PELP1 facilitates ERa crosstalk with
HER2 and Src kinases [9]. Recent studies show that
PELP1 interaction with lysine-specific demethylase KDM1
plays a key role in PELP1-mediated oncogenic functions
via KDM1-mediated epigenetic modifications [18].
We therefore examined whether the KDM1 blocker
pargyline will have clinical utility in blocking estrogen-
mediated breast tumorigenesis using preclinical xenograft
models. We used pargyline for our in vivo studies due to
its current US Food and Drug Administraion approval
and safety profile [29]. Nude mice (Nu/Nu) were injected
with either MCF-7 or MCF-7-PELP1 cells and implanted
with estradiol pellet. After establishment of tumors, five
mice (10 tumors) per group were treated with pargyline
(100 mg/kg in PBS, intraperitoneally, per day) for a
period of 6 weeks while control mice received daily
PBS injections. MCF-7-PELP1-driven tumors showed
aggressive growth compared with MCF-7 tumors (Fig-
ure 2A,B). No toxic effects were observed in behavioral
changes and body weights were not significantly differ-
ent between control and pargyline-treated groups (data
not shown). Pargyline treatment significantly reduced
the tumor volume by 62% and 77% in MCF-7 and MCF-
7-PELP1 xenografts, respectively, compared with con-
trol groups (Figure 2A,B). Pargyline-treated tumors
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revealed decreased proliferation, as evidenced by decreased
nuclear Ki-67 staining, and exhibited increased apoptosis,
as seen by TUNEL positivity (Figure 2C,D). These results
suggest that pargyline has therapeutic potential in redu-
cing breast tumor growth.
Pargyline treatment promotes inhibitory histone methyl
marks
KDM1, an enzyme that demethylates both H3K9me2 and
H3K4me2, and ER together with PELP1 regulate substrate
specificity of KDM1 from H3K4me2 to H3K9me2 [18].
To understand the mechanism, we examined whether
paragyline-mediated growth inhibition correlated with the
status of the inhibitory H3K9me2 mark at ERa target gene
promoters. Pargyline treatment significantly reduced the
growth of MCF-7, MCF-7-PELP1 and MCF-7-HER2 cells
in vitro with a 50% or more reduction in cell proliferation
of 4.5 mM, 1.5 mM and 3 mM, respectively, and pargyline
(3 mM) inhibited KDM1 activity in an in vitro demethyla-
tion assay (Figure S2A,B in Additional file 2).
MCF-7-PELP1 and MCF-7-HER2 cells were treated
with or without pargyline (3 mM) for 72 hours and chro-
matin was immunoprecipitated using H3K4me2,
H3K9me2 and H3K9Ac antibodies. Pargyline treatment
Figure 1 PELP1 knockdown impedes estrogen-mediated tumor growth. Nude mice implanted with estrogen pellets were injected
subcutaneously with MCF-7 cells. After 4 weeks, xenografts were treated with control-siRNA-DOPC or PELP1-siRNA-DOPC. Tumor growth was
measured at weekly intervals. (A) Immunohistochemistry (IHC) analysis of PELP1 expression in tumors treated with control or PELP1-siRNA-DOPC
(left panel). (B) Tumor volume. (C) Levels of H3K4me2, H2K9me2 and H3K9ac epigenetic marks were analyzed by IHC in tumors treated with
control or PELP1-siRNA-DOPC; quantitation performed as described in Materials and methods. Bar: standard error of the mean. *P < 0.05, **P <
0.001. DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; PELP1, proline glutamic acid and leucine-rich protein 1.
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increased the H3K4me2 status at the ERa target gene
GREB1C promoter in MCF-7-PELP1 cells (Figure 3A).
Interestingly, chromatin immunoprecipitation analysis
revealed that treatment with pargyline substantially
decreased expression of activation mark H3K9ac with a
concomitant increase in expression of repressive mark
H3K9me2 at GREB1C (Figure 3A). Similarly, KDM1
blockage by pargyline in MCF-7-HER2 model cells
increased H3K9me2 expression at the ERa KDM1 target
gene GREB1C promoter along with a significantly
decreased activation mark H3K9Ac (Figure 3B).
Observed inhibitory epigenetic modifications following
pargyline inhibitor treatment correlated with decreased
estrogen responsive element (ERE) reporter gene activity
and relative mRNA expression (Figure S2C,D,E in Addi-
tional file 2). IHC analysis of xenograft tumors that were
treated with pargyline revealed a substantial increase in
H3K9me2 staining (repressive marker) and decreased
H3K9Ac (activation marker) staining in pargyline-treated
tumors (Figure 3C,D). Collectively, these results indicate
that pargyline has the potential to promote inhibitory
markers at ERa target genes.
Figure 2 Pargyline reduces estrogen-mediated tumor growth. Nude mice implanted with estradiol pellets were injected subcutaneously
with (A) MCF-7 or (B) MCF-7-PELP1 model cells. After 4 weeks, mice were treated with or without pargyline (n = 10). Tumor growth was
measured at weekly intervals. Tumor volume is shown. Ki-67 expression and TUNEL analysis was done on (C) MCF-7 and (D) MCF-7-PELP1
xenografts that were treated with or without pargyline. Representative images are shown. Quantitation performed as described in Materials and
methods. ****P < 0.0001, **P < 0.001 *P < 0.05. PELP1, proline glutamic acid and leucine-rich protein 1; TUNEL, terminal deoxynucleotidyl
transferase dUTP nick end-labeling.
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Pargyline is effective in reducing oncogene-driven tumor
growth in a postmenopausal xenograft model
Our earlier studies indicated that the proto-oncogene
PELP1 promotes KDM1-driven epigenetic modifications
leading to local estrogen synthesis, contributing to cancer
cell proliferation and therapy resistance [19]. To examine
whether PELP1-driven breast tumors can be therapeuti-
cally targeted using pargyline, we performed in vivo
experiments using a postmenopausal xenograft model.
Ovariectomized nu/nu mice were injected with MCF-7
or MCF-7-PELP1 cells in an equal volume of Matrigel™
matrix. Athymic mice are deficient in adrenal androgens,
Figure 3 Pargyline promotes inhibitory epigenetic modifications. (A) MCF-7-PELP1 cells and (B) MCF-7-HER2 cells were treated with
pargyline (3 mM), and chromatin immunoprecipitation analysis was performed using H3K4me2-specific, H3K9me2-specific or H3K9ac-specific
antibodies and the status of epigenetic modifications was analyzed using real-time PCR with the estrogen receptor target gene GREB1C proximal
promoter-specific primers (B). Immunohistochemistry analysis of indicated epigenetic marks was done on (C) MCF-7 and (D) MCF-7-PELP1
xenografts that were treated with or without pargyline. Representative images are shown. Quantitation of staining performed as described in
Materials and methods. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. PAR, pargyline; PELP1, proline glutamic acid and leucine-rich protein 1.
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and therefore they were supplemented daily with subcu-
taneous injections of the aromatase substrate androstene-
dione (100 µg/day) for the duration of the experiment.
Under these conditions, injected MCF-7 cells did not
form tumors (data not shown). As observed before,
MCF-7-PELP1-expressing cells formed tumors in the
absence of exogenous estrogen supplementation - sug-
gesting that local derived estrogen supported the growth
of MCF-7-PELP1 cells. When the tumor volume reached
a palpable stage, mice (n = 5, 10 tumors) were either trea-
ted with pargyline (100 mg/kg in PBS, intraperitoneally,
per day) or vehicle (PBS).
Treatment of PELP1-driven breast tumors with par-
gyline reduced tumor volume by 78% (Figure 4A).
Immunohistochemical analysis of excised xenograft-
based tumors revealed a combined decrease in cellular
proliferation verified by reduced Ki-67 staining and
induced apoptosis as determined by TUNEL positivity
(Figure 4B). PELP1-deregulated tumors exhibited
excessive H3K4me2 activation markers, and pargyline
treatment substantially reduced H3K4me2 staining
with a concomitant increase in H3K9me2 inhibitory
epigenetic modification (Figure 4C; and Figure S3A in
Additional file 3). Earlier studies have shown that both
PELP1 and HER2 oncogenes promote activation of
ERa target genes as well as local estrogen synthesis via
upregulation of aromatase [14,30]. To test whether
pargyline treatment promotes inhibitory markers at the
aromatase promoter, we have examined the status of
the inhibitory H3K9me2 marker after treating both
MCF-7-PELP1 and MCF-7-HER2 model cells with par-
gyline. Results showed a substantial increase in the
inhibitory markers at the aromatase PI.3/II promoter
(Figure 4D). Accordingly, PELP1-driven xenograft
tumors showed increased expression of aromatase and
pargyline-mediated growth inhibition correlated with
decreased aromatase expression (Figure S3B in Addi-
tional file 3). These studies suggest that blockage of
KDM1 axis via pargyline has the potential to decrease
proto-oncogene PELP1-driven proliferation in vivo and
pargyline has the potential to reduce growth of onco-
gene and local estrogen-driven tumors.
Validation of therapeutic significance of KDM1 using
NCL-1
To independently validate the effect of pharmacological
inhibition of KDM1 on the growth of PELP1-driven
(MCF-7-PELP1) and HER2-driven (MCF-7-HER2) breast
cancer cells, we validated key findings using the recently
developed KDM1-specific inhibitor NCL-1 [22]. Both
model cells showed a reduction in cell proliferation upon
NCL-1 treatment (Figure 5A), with a 50% or more reduc-
tion in cell proliferation at a dose range of 12 to 16.5 μM.
MCF-7-PELP1 cells were treated with or without NCL-1
for 72 hours and chromatin was immunoprecipitated
using H3K4me2, H3K9me2 and H3K9ac antibodies.
Chromatin immunoprecipitation analysis using MCF-7-
PELP1 cells revealed that treatment with NCL-1 substan-
tially increased H4K4me2, and decreased expression of
activation marker H3K9Ac with a concomitant increase
in expression of repressive marker H3K9me2 at the aro-
matase 1.3/II promoter (Figure 5B). Similarly, KDM1
blockage by NCL1 also increased H3K9me2 levels at the
ER-KDM1 target gene GREB1C promoter along with a
decrease in the levels of activation marker H3K9ac
(Figure 5C). Observed inhibitory epigenetic modifications
following KDM1 inhibitor treatment correlated with
decreased relative mRNA expression, as assessed by
quantitative real-time PCR, of aromatase and the ER tar-
get GREB1C gene (Figure 5D). Collectively, these results
confirm findings we observed following pargyline treat-
ment and suggest that KDM1 blockers have the potential
to alter epigenetic changes promoted by oncogenes such
as PELP1 and HER2.
KDM1 blockers reduce proliferation of oncogene-driven
and therapy-resistant breast cancer cells
Deregulation of PELP1 and HER2 contributes to therapy
resistance [19]. We therefore examined whether inhibi-
tion of the PELP1-KDM1 axis using KDM1 blockers
would sensitize therapy-resistant model cells to hormo-
nal therapy. Combinatorial treatment of NCL-1 (10 μM)
with tamoxifen (100 nM) significantly reduced the pro-
liferation of three therapy-resistant model cells tested
(Figure 6A,B,C). Similarly, combinatorial treatment of
pargyline (3 mM) along with tamoxifen showed a signif-
icant effect on the growth of therapy-resistant model
cells (Figure 6D; and Figure S4 in Additional file 4).
Further, siRNA-mediated knockdown of PELP1 or
KDM1 expression also substantially reduced the growth
of therapy-resistant model cells (Figure S5 in Additional
file 5 and Figure S6 in Additional file 6). These results
suggested that KDM1 blockers have the potential to
reduce growth of oncogene-driven and therapy-resistant
breast cancer cells.
Discussion
Human ERa is implicated in breast cancer initiation and
progression. Despite the positive effects of hormonal
therapy using anti-estrogens and aromatase inhibitors, de
novo and/or acquired resistance to endocrine therapies
frequently occurs. Alternate therapies are urgently
needed to address this major clinical problem. In this
study, we tested the hypothesis that deregulation of
PELP1 promotes activation of KDM1-driven epigenetic
modifications at ERa target genes contributing to cancer
proliferation/therapy resistance by testing the therapeutic
effect of targeting the PELP1-KDM1 axis. We found that
Cortez et al. Breast Cancer Research 2012, 14:R108
http://breast-cancer-research.com/content/14/4/R108
Page 8 of 15
Figure 4 Pargyline reduces oncogene-driven tumor growth in a postmenopausal xenograft model. (A) Ovarectomized nude mice were
injected subcutaneously with MCF-7-PELP1 model cells. After 4 weeks, mice were treated with or without pargyline (n = 10). Tumor growth was
measured at weekly intervals. Tumor volume is shown. (B) Ki-67 expression as a marker of proliferation was analyzed by immunohistochemistry
(IHC). Quantitation of Ki-67 staining was performed using the Ki-67 index as described in Materials and methods. (C) IHC analysis of indicated
epigenetic marks was done on xenograft tumors that were treated with or without pargyline. (D) MCF-7-PELP1 and MCF-7-HER2 cells were
treated with pargyline (3 mM), and chromatin immunoprecipitation analysis was performed using H3K9me2 antibodies and the status of
epigenetic modification was analyzed using real-time PCR with aromatase P1.3/II promoter-specific primers. PELP1, proline glutamic acid and
leucine-rich protein 1.
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downregulation of PELP1 in vivo by PELP1 siRNA lipo-
somes significantly reduced estrogen-mediated breast
tumor progression in xenograft model; that drugs target-
ing KDM1 efficiently reduced PELP1-mediated increases
in breast cancer cell proliferation; that KDM1 blockers
sensitized therapy-resistant cells to hormonal therapy;
that treatment of PELP1 siRNA or KDM1 blockers sub-
stantially increased inhibitory histone methyl markers at
ER target promoters; and that KDM1 blockers also effi-
ciently reduced breast tumor growth in postmenopausal
xenograft models, where tumor growth is driven by local
estrogen. Collectively, our results implicate the PELP1-
KDM1 axis as a potential therapeutic target for breast
cancer.
Changes in ERa co-regulator expression have been
demonstrated to substantially contribute to ERa activity
and often correlate with poor prognosis. For example,
deregulation of the ERa co-regulators SRC3 (AIB1),
SRC2 and MTA1 was reported in breast tumors [7].
SRC3 knockout mice studies demonstrated that normal
expression of coactivator SRC3 is required for initiation
of tumorigenesis by carcinogens and oncogenes [31,32],
and overexpression of AIB1 in mouse mammary gland
promoted tumorigenesis [33]. Co-regulator PELP1 is
shown to function as a proto-oncogene [14] and was
recently demonstrated to be an independent prognostic
marker for poor breast cancer survival [17]. A recent
study suggests that PELP1 mediates androgen receptor
Figure 5 KDM1 blocker NCL-1 promotes inhibitory epigenetic modifications. (A) Model cells were treated with or without KDM1 inhibitor
(NCL-1) and cell proliferation was determined at indicated concentrations using the Cell Titer Glo assay. (B) MCF-7-PELP1 cells were treated with
or without NCL-1 (10 μM), and chromatin immunoprecipitation (ChIP) analysis was performed using H3K4me2-specific, H3K9me2-specific or
H3K9ac-specific antibodies and the status of epigenetic modifications was analyzed using real-time PCR with aromatase P1.3/II promoter-specific
primers. (C) MCF-7-HER2 cells were treated with or without NCL-1 (10 μM), and ChIP analysis was performed using H3K4me2-specific, H3K9me2-
specific or H3K9ac-specific antibodies and the status of epigenetic modifications was analyzed using real-time PCR with estrogen receptor target
gene GREB1C proximal promoter-specific primers. (D) MCF-7-PELP1 and MCF-7-HER2 cells were treated with NCL-1, total RNA was isolated and
expression of aromatase and GREB1 genes was analyzed by quantitative RT-PCR. Error bars indicate ± standard error of the mean. Statistical
significance determined by Student’s t test. ***P < 0.001, **P < 0.01, *P < 0.05. KDM1, lysine-specific histone demethylase 1; NCL-1, N-((1S)-3-(3-
(trans-2-aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)propyl)benzamide; PELP1, proline glutamic acid and leucine-rich protein 1.
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activation in the absence of androgens in PCa cells and
that disruption of the complex between androgen recep-
tor and PELP1 may be a viable therapeutic strategy in
advanced prostate cancer [34]. We found that systemic
administration of PELP1 siRNA in a nanoliposomal for-
mulation (PELP1-siRNA-DOPC) significantly reduced
breast tumor growth in a xenograft model. IHC analysis
of excised xenograft-based tumors revealed a combined
Figure 6 KDM1 blockers reduce proliferation of oncogene-driven and therapy-resistant breast cancer cells. Therapy-resistant (A) MCF-7-
HER2, (B) MCF-7-PELP1 and (C) MCF-7-TamR model cells were treated with or without NCL-1 (10 μM) alone or in combination with tamoxifen
(Tam) or letrozole (Let), and cell proliferation was determined. (D) MCF-7-TamR cells were treated with or without KDM1 inhibitor (pargyline, 3
mM) alone or in combination with tamoxifen (Tam) or letrozole (Let), and cell proliferation was determined using the Cell Titer Glo assay. All
experimental data points used are generated from three biological replicates. Statistical significance determined by Student’s t test. ***P < 0.001,
**P < 0.01, *P < 0.05. KDM1, lysine-specific histone demethylase 1; NCL-1, N-((1S)-3-(3-(trans-2-aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)
propyl)benzamide; PELP1, proline glutamic acid and leucine-rich protein 1.
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decrease in cellular proliferation, induction of apoptosis
and upregulation of inhibitory epigenetic modifications
of histone H3K9me2 compared with nontreated control
groups. These findings suggest that blocking PELP1
expression and/or actions represent an indirect means of
targeting the activity of ERa and that blocking the PELP1
axis could have therapeutic implications for reducing
breast cancer growth.
Histone methylation plays a vital role in many neoplas-
tic processes and thus represents a valuable therapeutic
target [35-37]. Recent evidence suggests activation or
repression of estrogen-induced genes depends on the
modulation of histone methyl markers on target gene
promoters [38]. Histone demethylase KDM1 belongs to a
growing number of transcriptional complexes that are
implicated in tumorigenesis [39] and is recruited to a sig-
nificant fraction of ERa target genes [13]. Our previous
studies indicate that PELP1 is a novel co-regulator that
participates in ERa-mediated chromatin remodeling
events via its interactions with KDM1 [18]. Pargyline
(Eutonyl, Supirdyl, Eutron) is a US Food and Drug
Administration-approved drug to treat depression and
vascular hypertension. Several recent studies demon-
strated that pargyline has the potential to inhibit KDM1.
Here we utilized pargyline to examine whether it has the
potential to restore altered epigenetic changes in PELP1-
driven breast cancer. Our results showed a significant
effect of pargyline in reducing PELP1-driven prolifera-
tion. Further, pargyline-treated xenograft tissues showed
inhibition of in vivo KDM1 activity as can be seen by
increased levels of H3K4me2 and H3K9me2, known sub-
strates of KDM1. This proof-of-principle study demon-
strated the significance of the PELP1-KDM1 axis in
curbing breast cancer progression. However, an extended
period of pargyline use at millimolar concentrations may
cause side effects. To overcome this possibility, we are
currently developing better inhibitors of KDM1 that
work efficiently at lower doses with high specificity - we
have developed the compound NCL-1, which showed sig-
nificant activity in the 5 to 10 μM range. Pargyline-
mediated inhibition of breast cancer cell growth was
independently validated using the more potent KDM1
inhibitor (NCL-1) and also by using PELP1 and KDM1
siRNAs. Recent studies demonstrating the efficacy of
KDM1 inhibitors on reducing growth of neuroblastoma
[40] and cancer stem cells [41] also corroborate our find-
ings using breast cancer models.
KDM1 can potentially function as a coactivator or co-
repressor by demethylating H3K9 or H3K4, respectively,
and co-regulators such as PELP1 in conjunction with ERa
modulate KDM1 specificity from H3K4me2 to H3K9me2,
leading to enhanced ERa target gene activation [42]. As
expected, blockage of KDM1 via pargyline or NCL-1
increased both H3K4me2 and H3K9me2 methylation in
MCF-7-PELP1 cells. A significant increase in H3K4
methylation in MCF-7-PELP1 model cells also suggests
that lack of KDM1 activity facilitated unopposed action of
methylases and that PELP1 has the potential to enhance
H3K4 methylation via facilitation of H3K4me2 methylases.
The latter potential is supported by emerging findings that
PELP1 associates with histone methylases [15] and due to
the fact that PELP1 knockdown significantly reduced
H3K4 methylation (Figure 1C). Pargyline-mediated block-
age of KDM1 functions may also strongly increase
the repressive H3K9me2 marker, and its subsequent
conversion to H3K9me3 marker may lead to reduced
recruitment of H3K9 acetyltransferases at specific gene
promoters. In support of the second possibility, our
ongoing studies identified SETDB1 (an enzyme that facili-
tates conversion of H3K9me2 to H3K9me3) as a PELP1
interacting protein and showed a reduction of activation
marker H3K9Ac in pargyline or NCL-1-treated cells, and
earlier studies reported the existence of SETDB1, KDM1
and PELP1 complexes [15]. Blockage of KDM1 functions
may provide a favorable environment for SETDB1 to con-
vert H3K9me2 to H3K9me3 under conditions of pargyline
treatment. However, future studies are needed to discern
these possibilities.
Deregulation of HER2 expression and downstream sig-
naling has emerged as a significant factor in the develop-
ment of hormonal resistance, and crosstalk with ERa has
been shown to promote endocrine therapy resistance [43].
PELP1 interacts with HER2 and is implicated in facilitating
ER crosstalk with HER2 signaling pathways [9]. Deregu-
lated PELP1 expression during breast cancer progression
is associated with more invasive disease [16,17]. Addition-
ally, PELP1 is shown to contribute to HER2-mediated
local estrogen synthesis via increased aromatase expres-
sion [14]. Our findings suggest that KDM1 targeting inhi-
bitors (pargyline and NCL-1) are efficient in reducing
PELP1-mediated HER2-ERa crosstalk. KDM1 inhibitors
efficiently reversed HER2-mediated epigenetic changes
and promoted inhibitory histone methyl markers at ERa
target genes.
Although mechanisms for hormonal therapy resistance
remain elusive, emerging data implicate ERa crosstalk
with growth factor pathways and deregulation of co-
regulators as major causes of resistance [44]. Earlier
studies showed that PELP1 deregulation contributes to
therapy resistance [15,45]. Because PELP1 interacts with
epigenetic modifier KDM1 [18], in this study we tested
whether inhibition of KDM1 by inhibitor pargyline
reduced the viability of resistant cells. Combinatorial
therapy of anti-estrogen (tamoxifen) with pargyline or
NCL-1 showed the most promising therapeutic effect
compared with single-agent therapy to inhibit growth of
therapy-resistant cells. Results suggest that targeting of
the PELP1-KDM1 axis in combination with current
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endocrine therapies increases therapeutic efficacy
and may inhibit or delay development of aromatase inhi-
bitor resistance by promoting favorable epigenetic
modifications.
Local estrogen production via deregulated expression
of aromatase (Cyp19), the key enzyme in the biosynthesis
of estrogen, contributes to tumor progression in postme-
nopausal women [46]. Aromatase inhibitors are effective
in enhancing patient survival although long-term use is
limited by systemic side effects and therapy resistance
[47]. Recent studies from our laboratory demonstrated
PELP1 cooperates with HER2 and modulates epigenetic
changes at the aromatase promoter by interacting with
lysine-specific demethylase (KDM1), leading to local
estrogen synthesis [48]. In this study, we found that
KDM1 inhibitors substantially inhibited growth of local
estrogen-producing cells (MCF-7-PELP1 and MCF-7-
HER2). In the postmenopausal xenograft-based model,
treatment with pargyline significantly inhibited the
growth of local estrogen-producing PELP1 tumor cells.
Our results suggest that drugs targeting the PELP1-
KDM1 axis are effective in reversing the methyl modifi-
cations at the aromatase promoter that are affected by
proto-oncogenes such as PELP1 and HER2 and for
blocking growth of local estrogen-producing cells.
Conclusion
In summary, our data provide the first in vivo evidence
demonstrating that the PELP1-KDM1 axis is a potential
therapeutic target for breast cancer and that targeting the
PELP-KDM1 axis has the potential to reduce therapy
resistance and local estrogen synthesis. Combining emer-
ging KDM1 targeting drugs with current endocrine
therapies, therefore, has the potential to impede growth
of co-regulator-deregulated tumors and to restore sensi-
tivity of therapy-resistant breast cancer cells to treatment.
Additional material
Additional file 1: Figure S1 showing that PELP1 knockdown
decreases xenograft tumor proliferation and increases apoptosis.
Nude mice implanted with estrogen pellets were injected
subcutaneously with MCF-7 cells. After 4 weeks, xenografts were treated
with control-siRNA-DOPC or PELP1-siRNA-DOPC. (A) Ki-67 expression as a
marker of proliferation was analyzed by IHC. (B) TUNEL staining was
performed as a marker of apoptosis on tumors that were treated with
control-siRNA-DOPC or PELP1-siRNA-DOPC. Quantitation was performed
as described in Materials and methods. **P < 0.001.
Additional file 2: Figure S2 showing that pargyline reduces
proliferation of oncogene-driven breast cancer cells. (A) Model cells
were treated with or without pargyline and cell proliferation was
determined at indicated concentrations using the Cell Titer Glo assay. (B)
Total histones purified from MCF-7 cells were incubated with purified
KDM1 in the presence of the KDM1 inhibitor pargyline (3 mM) or NCL-1
(15 mM) in a standard in vitro demethylation assay. Western blot analysis
was performed using the total H3 and H3K4-methyl2-specific antibodies.
(C) Western analysis of PELP1 levels in MCF-7, MCF-7-PELP1, and MCF-7-
HER2 model cells. (D) Model cells were transfected with ERE reporter,
after 72 hours, cells were treated with or without pargyline (3 mM) and
reporter activity was measured after 12 hours. (E) MCF-7-HER2 cells were
treated with pargyline (3 mM), total RNA was isolated and expression of
GREB1 genes was analyzed by quantitative RT-PCR. Error bars indicate ±
standard error of the mean. Statistical significance determined by
Student’s t test.*P < 0.05.
Additional file 3: Figure S3 showing that pargyline reduces
oncogene-driven tumor growth in a postmenopausal xenograft
model. (A) IHC analysis of indicated epigenetic marks was done on
xenograft tumors that were treated with or without pargyline. (B) IHC
analysis of aromatase expression was done on xenograft tumors that
were treated with or without pargyline. ***P < 0.0001.
Additional file 4: Figure S4 showing that pargyline sensitizes
therapy-resistant cells to hormonal therapy. Letrozole-resistant cells
(MCF-7-LTLT) were treated with or without KDM1 inhibitor (pargyline)
alone or in combination with letrozole (10-6 M) or tamoxifen (10-7 M)
and cell proliferation was determined using the Cell Titer Glo assay. **P <
0.001, *P < 0.05.
Additional file 5: Figure S5 showing that PELP1 knockdown reduces
the growth of therapy-resistant cells. Therapy-resistant breast cancer
cells were transfected with PELP1 siRNA (50 pmol) or control siRNA (50
pmol), and after 72 hours cell viability was measured by ATP assay (Cell
Titer Glo ATP assay; Promega). **P < 0.001.
Additional file 6: Figure S6 showing that KDM1 knockdown reduces
the growth of therapy-resistant cells. (A) Therapy-resistant breast
cancer cells were transfected with KDM1 siRNA (50 pmol) or control siRNA
(50 pmol), and after 24 hours were treated with tamoxifen (10-7 M). After
72 hours, cell viability was measured by MTT assay. **P < 0.001. (B)
Western analysis of KDM1 using total lysates from control-siRNA and
KDM1-siRNA transfected cells demonstrating the efficiency of KDM1
knockdown.
Abbreviations
DOPC: 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; ER: estrogen receptor;
HER2: human epidermal growth factor receptor 2; IHC:
immunohistochemistry; KDM1: lysine-specific histone demethylase 1; LTLTca:
long-term letrozole treated MCF-7ca; NCL-1: N-((1S)-3-(3-(trans-2-
aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)propyl)benzamide; PBS:
phosphate-buffered saline; PCR: polymerase chain reaction; PELP1: proline
glutamic acid and leucine-rich protein 1; RT: reverse transcriptase; siRNA:
small interfering RNA; TamR: tamoxifen-resistant; TUNEL: terminal
deoxynucleotidyl transferase dUTP nick end-labeling.
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